Literature DB >> 33959997

Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE).

Srikanth Muppidi1, Richard J Nowak2, Amanda C Guidon3, Jeffrey T Guptill4, Michael K Hehir5, Katherine Ruzhansky6, Leeann B Burton3, David Post1, Gary Cutter7, Robin Conwit8, Nicte I Mejia3, Henry J Kaminski9, James F Howard10.   

Abstract

INTRODUCTION/AIMS: Telemedicine may be particularly well-suited for myasthenia gravis (MG) due to the disorder's need for specialized care, its hallmark fluctuating muscle weakness, and the potential for increased risk of virus exposure among patients with MG during the coronavirus disease 2019 (COVID-19) pandemic during in-person clinical visits. A disease-specific telemedicine physical examination to reflect myasthenic weakness does not currently exist.
METHODS: This paper outlines step-by-step guidance on the fundamentals of a telemedicine assessment for MG. The Myasthenia Gravis Core Exam (MG-CE) is introduced as a MG-specific, telemedicine, physical examination, which contains eight components (ptosis, diplopia, facial strength, bulbar strength, dysarthria, single breath count, arm strength, and sit to stand) and takes approximately 10 minutes to complete.
RESULTS: Pre-visit preparation, remote ascertainment of patient-reported outcome scales and visit documentation are also addressed. DISCUSSION: Additional knowledge gaps in telemedicine specific to MG care are identified for future investigation.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  COVID-19; myasthenia gravis; outcome measures; physcial examination; telemedicine

Mesh:

Year:  2021        PMID: 33959997      PMCID: PMC9057373          DOI: 10.1002/mus.27260

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.852


  14 in total

1.  A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score.

Authors:  Donald B Sanders; Bernadette Tucker-Lipscomb; Janice M Massey
Journal:  Ann N Y Acad Sci       Date:  2003-09       Impact factor: 5.691

Review 2.  Recommendations for the Implementation of Telehealth in Cardiovascular and Stroke Care: A Policy Statement From the American Heart Association.

Authors:  Lee H Schwamm; Neale Chumbler; Ed Brown; Gregg C Fonarow; David Berube; Karin Nystrom; Robert Suter; Mirian Zavala; Daniel Polsky; Kavita Radhakrishnan; Nathaniel Lacktman; Katherine Horton; Mary-Beth Malcarney; John Halamka; A Colby Tiner
Journal:  Circulation       Date:  2016-12-20       Impact factor: 29.690

Review 3.  The myasthenia gravis--specific activities of daily living profile.

Authors:  Srikanth Muppidi
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

4.  The digital divide in adoption and use of a personal health record.

Authors:  Cyrus K Yamin; Srinivas Emani; Deborah H Williams; Stuart R Lipsitz; Andrew S Karson; Jonathan S Wald; David W Bates
Journal:  Arch Intern Med       Date:  2011-03-28

Review 5.  The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders.

Authors:  Bastiaan R Bloem; E Ray Dorsey; Michael S Okun
Journal:  JAMA Neurol       Date:  2020-08-01       Impact factor: 18.302

6.  Outcome Measures in Myasthenia Gravis: Incorporation Into Clinical Practice.

Authors:  Srikanth Muppidi
Journal:  J Clin Neuromuscul Dis       Date:  2017-03

7.  Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action.

Authors:  Irl B Hirsch; Joe Martinez; E Ray Dorsey; Gerald Finken; Alexander Fleming; Chris Gropp; Philip Home; Daniel I Kaufer; Spyros Papapetropoulos
Journal:  Clin Ther       Date:  2017-04-14       Impact factor: 3.393

8.  International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r.

Authors:  Ted M Burns; Reza Sadjadi; Kimiaki Utsugisawa; Kelly G Gwathmey; Amruta Joshi; Sarah Jones; Vera Bril; Carolina Barnett; Jeffrey T Guptill; Donald B Sanders; Lisa Hobson-Webb; Vern C Juel; Janice Massey; Karissa L Gable; Nicholas J Silvestri; Gil Wolfe; Gary Cutter; Yuriko Nagane; Hiroyuki Murai; Masayuki Masuda; Maria Elena Farrugia; Caroline Carmichael; Simone Birnbaum; Jean-Yves Hogrel; Shahriar Nafissi; Farzad Fatehi; Changyi Ou; Weibin Liu; Mark Conaway
Journal:  Muscle Nerve       Date:  2016-11-07       Impact factor: 3.217

9.  Primer on the In-home Teleneurologic Examination: A COVID-19 Pandemic Imperative.

Authors:  Christopher J Boes; Andrea N Leep Hunderfund; Jennifer M Martinez-Thompson; Neeraj Kumar; Rodolfo Savica; Jeremy K Cutsforth-Gregory; Lyell K Jones
Journal:  Neurol Clin Pract       Date:  2021-04

10.  Teleneurology during the COVID-19 pandemic: A step forward in modernizing medical care.

Authors:  Bhaskar Roy; Richard J Nowak; Ricardo Roda; Babar Khokhar; Huned S Patwa; Thomas Lloyd; Seward B Rutkove
Journal:  J Neurol Sci       Date:  2020-05-21       Impact factor: 3.181

View more
  3 in total

Review 1.  A Comprehensive Review of Neuromuscular Manifestations of COVID-19 and Management of Pre-Existing Neuromuscular Disorders in Children.

Authors:  Daniel J Goetschius; Yunsung Kim; Ashutosh Kumar; Dustin Paul; Sunil Naik
Journal:  J Clin Med       Date:  2022-02-11       Impact factor: 4.241

2.  Development and validation of the Myasthenia Gravis TeleScore (MGTS).

Authors:  F Pasqualin; S V Guidoni; E Albertini; M Ermani; R Frangiamore; F Vanoli; C Antozzi; R Mantegazza; D M Bonifati
Journal:  Neurol Sci       Date:  2022-02-28       Impact factor: 3.307

3.  Patient preference for virtual versus in-person visits in neuromuscular clinical practice.

Authors:  Komal Hafeez; Hani Kushlaf; Husam Al-Sultani; Anny-Claude Joseph; Zoya Zaeem; Zaeem Siddiqi; Shannon Laboy; Michael Pulley; Ali A Habib; Nathaniel M Robbins; Sean Zadeh; Muhammad Ubaid Hafeez; Yessar Hussain; Alexandria Melendez-Zaidi; Charles Kassardjian; Kristin Johnson; Holly Leonhard; Suur Biliciler; Jorge E Patino Murillas; Aziz I Shaibani
Journal:  Muscle Nerve       Date:  2022-06-03       Impact factor: 3.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.